project id: TCGA-BLCA; case submitter id: TCGA-CF-A5UA; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.85; concentration: 0.17; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.9; rna integrity number: 8.6; age at index: 67; days to birth: -24625; ethnicity: not hispanic or latino; gender: male; race: asian; vital status: Alive; year of birth: 1945; age at diagnosis: 24625; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 365.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 1.643835616438356; pack years smoked: 30.0; is ffpe: false; composition: Not Reported; days to collection: 84; days to sample procurement: 0; initial weight: 320.0; portion submitter id: TCGA-CF-A5UA-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 10.0; percent tumor cells: 90.0; percent tumor nuclei: 95.0;